Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 73, No 2 (2022)
Original paper
Submitted: 2021-12-31
Accepted: 2022-04-01
Published online: 2022-04-19
View PDF Download PDF file View HTML
Get Citation

The relationships between selected serum adipokines and thyroid function in patients with obesity

Krzysztof Walczak1, Lucyna Siemińska2
DOI: 10.5603/EP.a2022.0030
·
Pubmed: 35593684
·
Endokrynol Pol 2022;73(2):353-360.
Affiliations
  1. Department of Thoracic Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland
  2. Department of Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland

open access

Vol 73, No 2 (2022)
Original Paper
Submitted: 2021-12-31
Accepted: 2022-04-01
Published online: 2022-04-19

Abstract

Introduction: The study was designed to evaluate the effect of thyroid function on serum levels of different adipokines in obesity. We investigated relationships between the thyroid axis and serum levels of leptin, adiponectin, and chemerin, and we assessed the influence of autoimmune thyroiditis (AIT) on those relations.

Material and methods: The participants of this study included 181 euthyroid patients (147 women and 34 men) with obesity [body mass index (BMI) 30–39.9 kg/m2] and severe (morbid) obesity (BMI ≥ 40 kg/m2), aged 18 to 65 years. We divided all obese patients by thyrotropic hormone (TSH) tertiles, and we compared all participants according to BMI. Patients were further divided into the following subgroups: with chronic autoimmune thyroiditis and without autoimmune thyroiditis.

Results: Comparison of obese patients according to TSH tertile showed significantly higher serum concentrations of leptin, chemerin, and thyroid antibodies and an increased leptin/adiponectin ratio in the group with high normal TSH. We observed statistically significant correlations between serum TSH and BMI, leptin, chemerin, thyroid peroxidase antibodies, and the leptin/adiponectin ratio. In patients diagnosed with autoimmune thyroiditis, higher levels of antibodies and TSH were found, but there were no differences in homeostatic model assessment index (HOMA-I), the leptin/adiponectin ratio, and adipokine levels. In obese patients the relationships between serum leptin, chemerin, the leptin/adiponectin ratio, and BMI were dependent on each other.

Conclusion: Serum leptin, chemerin, the leptin/adiponectin ratio, and BMI are significantly higher in patients with high normal TSH; however, selected adipokines are not related to the presence of autoimmune thyroiditis. There are interplays between TSH, adipokines, and obesity, but how these relationships are related remains unknown.

Abstract

Introduction: The study was designed to evaluate the effect of thyroid function on serum levels of different adipokines in obesity. We investigated relationships between the thyroid axis and serum levels of leptin, adiponectin, and chemerin, and we assessed the influence of autoimmune thyroiditis (AIT) on those relations.

Material and methods: The participants of this study included 181 euthyroid patients (147 women and 34 men) with obesity [body mass index (BMI) 30–39.9 kg/m2] and severe (morbid) obesity (BMI ≥ 40 kg/m2), aged 18 to 65 years. We divided all obese patients by thyrotropic hormone (TSH) tertiles, and we compared all participants according to BMI. Patients were further divided into the following subgroups: with chronic autoimmune thyroiditis and without autoimmune thyroiditis.

Results: Comparison of obese patients according to TSH tertile showed significantly higher serum concentrations of leptin, chemerin, and thyroid antibodies and an increased leptin/adiponectin ratio in the group with high normal TSH. We observed statistically significant correlations between serum TSH and BMI, leptin, chemerin, thyroid peroxidase antibodies, and the leptin/adiponectin ratio. In patients diagnosed with autoimmune thyroiditis, higher levels of antibodies and TSH were found, but there were no differences in homeostatic model assessment index (HOMA-I), the leptin/adiponectin ratio, and adipokine levels. In obese patients the relationships between serum leptin, chemerin, the leptin/adiponectin ratio, and BMI were dependent on each other.

Conclusion: Serum leptin, chemerin, the leptin/adiponectin ratio, and BMI are significantly higher in patients with high normal TSH; however, selected adipokines are not related to the presence of autoimmune thyroiditis. There are interplays between TSH, adipokines, and obesity, but how these relationships are related remains unknown.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

adipokines; thyroid; obesity

About this article
Title

The relationships between selected serum adipokines and thyroid function in patients with obesity

Journal

Endokrynologia Polska

Issue

Vol 73, No 2 (2022)

Article type

Original paper

Pages

353-360

Published online

2022-04-19

Page views

5259

Article views/downloads

761

DOI

10.5603/EP.a2022.0030

Pubmed

35593684

Bibliographic record

Endokrynol Pol 2022;73(2):353-360.

Keywords

adipokines
thyroid
obesity

Authors

Krzysztof Walczak
Lucyna Siemińska

References (57)
  1. Perello M, Stuart RC, Nillni EA. The role of intracerebroventricular administration of leptin in the stimulation of prothyrotropin releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology. 2006; 147(7): 3296–3306.
    CrossRefPubMed
  2. García-Solís P, García OP, Hernández-Puga G, et al. Thyroid hormones and obesity: a known but poorly understood relationship. Endokrynol Pol. 2018; 69(3): 292–303.
    CrossRefPubMed
  3. al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab. 1997; 82(4): 1118–1125.
    CrossRefPubMed
  4. Lu S, Guan Q, Liu Y, et al. Role of extrathyroidal TSHR expression in adipocyte differentiation and its association with obesity. Lipids Health Dis. 2012; 11: 17.
    CrossRefPubMed
  5. Santini F, Galli G, Maffei M, et al. Acute exogenous TSH administration stimulates leptin secretion in vivo. Eur J Endocrinol. 2010; 163(1): 63–67.
    CrossRefPubMed
  6. Bétry C, Challan-Belval MA, Bernard A, et al. Increased TSH in obesity: Evidence for a BMI-independent association with leptin. Diabetes Metab. 2015; 41(3): 248–251.
    CrossRefPubMed
  7. Gómez-Zamudio JH, Mendoza-Zubieta V, Ferreira-Hermosillo A, et al. High Thyroid-stimulating Hormone Levels Increase Proinflammatory and Cardiovascular Markers in Patients with Extreme Obesity. Arch Med Res. 2016; 47(6): 476–482.
    CrossRefPubMed
  8. Janson A, Karlsson FA, Micha-Johansson G, et al. Effects of stimulatory and inhibitory thyrotropin receptor antibodies on lipolysis in infant adipocytes. J Clin Endocrinol Metab. 1995; 80(5): 1712–1716.
    CrossRefPubMed
  9. Gagnon A, Antunes TT, Ly T, et al. Thyroid-stimulating hormone stimulates lipolysis in adipocytes in culture and raises serum free fatty acid levels in vivo. Metabolism. 2010; 59(4): 547–553.
    CrossRefPubMed
  10. Felske D, Gagnon A, Sorisky A. Interacting Effects of TSH and Insulin on Human Differentiated Adipocytes. Horm Metab Res. 2015; 47(9): 681–685.
    CrossRefPubMed
  11. Delitala AP, Steri M, Fiorillo E, et al. Adipocytokine correlations with thyroid function and autoimmunity in euthyroid sardinians. Cytokine. 2018; 111: 189–193.
    CrossRefPubMed
  12. Shao Ss, Zhao Yf, Song Yf, et al. Dietary high-fat lard intake induces thyroid dysfunction and abnormal morphology in rats. Acta Pharmacol Sin. 2014; 35(11): 1411–1420.
    CrossRefPubMed
  13. Ma S, Jing F, Xu C, et al. Thyrotropin and obesity: increased adipose triglyceride content through glycerol-3-phosphate acyltransferase 3. Sci Rep. 2015; 5: 7633.
    CrossRefPubMed
  14. Lai Y, Wang J, Jiang F, et al. The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J. 2011; 58(1): 23–30.
    CrossRefPubMed
  15. Layegh P, Asadi A, Jangjoo A, et al. "Comparison of thyroid volume, TSH, free t4 and the prevalence of thyroid nodules in obese and non-obese subjects and correlation of these parameters with insulin resistance status". Caspian J Intern Med. 2020; 11(3): 278–282.
    CrossRefPubMed
  16. Bjergved L, Jørgensen T, Perrild H, et al. Thyroid function and body weight: a community-based longitudinal study. PLoS One. 2014; 9(4): e93515.
    CrossRefPubMed
  17. Finucane FM, Luan J, Wareham NJ, et al. (on behalf of the European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group). Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009; 52(11): 2345–2349.
    CrossRefPubMed
  18. Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018; 7(1): 57–62.
    CrossRefPubMed
  19. Oda N, Imamura S, Fujita T, et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism. 2008; 57(2): 268–273.
    CrossRefPubMed
  20. Antunes TT, Gagnon A, Bell A, et al. Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obes Res. 2005; 13(12): 2066–2071.
    CrossRefPubMed
  21. van Tienhoven-Wind LJN, Dullaart RPF. Increased leptin/adiponectin ratio relates to low-normal thyroid function in metabolic syndrome. Lipids Health Dis. 2017; 16(1): 6.
    CrossRefPubMed
  22. Al Mohareb O, Al Saqaaby M, Ekhzaimy A, et al. The Relationship Between Thyroid Function and Body Composition, Leptin, Adiponectin, and Insulin Sensitivity in Morbidly Obese Euthyroid Subjects Compared to Non-obese Subjects. Clin Med Insights Endocrinol Diabetes. 2021; 14: 1179551420988523.
    CrossRefPubMed
  23. Prummel MF, Wiersinga WM. Thyroid peroxidase autoantibodies in euthyroid subjects. Best Pract Res Clin Endocrinol Metab. 2005; 19(1): 1–15.
    CrossRefPubMed
  24. Liu J, Duan Y, Fu J, et al. Association Between Thyroid Hormones, Thyroid Antibodies, and Cardiometabolic Factors in Non-Obese Individuals With Normal Thyroid Function. Front Endocrinol (Lausanne). 2018; 9: 130.
    CrossRefPubMed
  25. Marzullo P, Minocci A, Tagliaferri MA, et al. Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. J Clin Endocrinol Metab. 2010; 95(8): 3965–3972.
    CrossRefPubMed
  26. Tsigalou C, Vallianou N, Dalamaga M. Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity? Curr Obes Rep. 2020; 9(3): 245–254.
    CrossRefPubMed
  27. Mahdavi M, Amouzegar A, Mehran L, et al. Investigating the prevalence of primary thyroid dysfunction in obese and overweight individuals: Tehran thyroid study. BMC Endocr Disord. 2021; 21(1): 89.
    CrossRefPubMed
  28. Baranowska-Bik A, Bik W. The Association of Obesity with Autoimmune Thyroiditis and Thyroid Function-Possible Mechanisms of Bilateral Interaction. Int J Endocrinol. 2020; 2020: 8894792.
    CrossRefPubMed
  29. Duntas LH, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013; 23(6): 646–653.
    CrossRefPubMed
  30. Fresno M, Alvarez R, Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem. 2011; 117(3): 151–164.
    CrossRefPubMed
  31. Adamska A, Popławska-Kita A, Siewko K, et al. Body Composition and Serum Anti-Müllerian Hormone Levels in Euthyroid Caucasian Women With Hashimoto Thyroiditis. Front Endocrinol (Lausanne). 2021; 12: 657752.
    CrossRefPubMed
  32. Gao Y, Sheng M, Zhao Y, et al. Serum Chemerin and thyrotropin expression levels in patients with thyroid cancer and roles in predicting survival. Int J Clin Exp Med. 2019; 12: 7561–7568.
  33. Gong N, Gao C, Chen X, et al. Adipokine expression and endothelial function in subclinical hypothyroidism rats. Endocr Connect. 2018; 7(2): 295–304.
    CrossRefPubMed
  34. Chen X, Gao C, Gong N, et al. The Change of Left Ventricular Function in Rats with Subclinical Hypothyroid and the Effects of Thyroxine Replacement. Int J Endocrinol. 2018; 2018: 8682765.
    CrossRefPubMed
  35. Alshaikh EM, Omar UM, Alsufiani HM, et al. The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin. Int J Health Sci (Qassim). 2019; 13(2): 44–47.
    PubMed
  36. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282(38): 28175–28188.
    CrossRefPubMed
  37. Habib SS, Eshki A, AlTassan B, et al. Relationship of serum novel adipokine chemerin levels with body composition, insulin resistance, dyslipidemia and diabesity in Saudi women. Eur Rev Med Pharmacol Sci. 2017; 21(6): 1296–1302.
    PubMed
  38. Lu B, Zhao M, Jiang W, et al. Independent Association of Circulating Level of Chemerin With Functional and Early Morphological Vascular Changes in Newly Diagnosed Type 2 Diabetic Patients. Medicine (Baltimore). 2015; 94(47): e1990.
    CrossRefPubMed
  39. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes. 2009; 58(12): 2731–2740.
    CrossRefPubMed
  40. Stepan H, Philipp A, Roth I, et al. Serum levels of the adipokine chemerin are increased in preeclampsia during and 6 months after pregnancy. Regul Pept. 2011; 168(1-3): 69–72.
    CrossRefPubMed
  41. Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009; 161(2): 339–344.
    CrossRefPubMed
  42. Fülöp P, Seres I, Lőrincz H, et al. Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol Med. 2014; 18(7): 1313–1320.
    CrossRefPubMed
  43. Sanchez-Rebordelo E, Cunarro J, Perez-Sieira S, et al. Regulation of Chemerin and CMKLR1 Expression by Nutritional Status, Postnatal Development, and Gender. Int J Mol Sci. 2018; 19(10).
    CrossRefPubMed
  44. Hutcheson J. Adipokines influence the inflammatory balance in autoimmunity. Cytokine. 2015; 75(2): 272–279.
    CrossRefPubMed
  45. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010; 21(11): 660–667.
    CrossRefPubMed
  46. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci (Lond). 2021; 135(6): 731–752.
    CrossRefPubMed
  47. Mohammed Ali DM, Al-Fadhel SZ, Al-Ghuraibawi NH, et al. Serum chemerin and visfatin levels and their ratio as possible diagnostic parameters of rheumatoid arthritis. Reumatologia. 2020; 58(2): 67–75.
    CrossRefPubMed
  48. Gonzalez-Ponce F, Gamez-Nava JI, Perez-Guerrero EE, et al. Research Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders. Serum chemerin levels: A potential biomarker of joint inflammation in women with rheumatoid arthritis. PLoS One. 2021; 16(9): e0255854.
    CrossRefPubMed
  49. Tomalka-Kochanowska J, Baranowska B, Wolinska-Witort E, et al. Plasma chemerin levels in patients with multiple sclerosis. Neuro Endocrinol Lett. 2014; 35(3): 218–223.
    PubMed
  50. Nakajima H, Nakajima K, Nagano Y, et al. Circulating level of chemerin is upregulated in psoriasis. J Dermatol Sci. 2010; 60(1): 45–47.
    CrossRefPubMed
  51. De Palma G, Castellano G, Del Prete A, et al. The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int. 2011; 79(11): 1228–1235.
    CrossRefPubMed
  52. Zhou Q, Fu Yu, Hu L, et al. Relationship of circulating chemerin and omentin levels with Th17 and Th9 cell immune responses in patients with asthma. J Asthma. 2018; 55(6): 579–587.
    CrossRefPubMed
  53. Ganguly D, Haak S, Sisirak V, et al. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013; 13(8): 566–577.
    CrossRefPubMed
  54. Janyga S, Marek B, Kajdaniuk D, et al. CD4+ cells in autoimmune thyroid disease. Endokrynol Pol. 2021; 72(5): 572–583.
    CrossRefPubMed
  55. Stasiołek M, Śliwka PW, Stasiak M, et al. Dendritic cells in autoimmune disorders and cancer of the thyroid. Folia Histochem Cytobiol. 2014; 52(1): 18–28.
    CrossRefPubMed
  56. Bogusławska J, Godlewska M, Gajda E, et al. Cellular and molecular basis of thyroid autoimmunity. Eur Thyroid J. 2022; 11(1).
    CrossRefPubMed
  57. Berta E, Harangi M, Varga VE, et al. Evaluation of serum chemerin level in patients with hashimoto's thyroiditis. Atherosclerosis. 2016; 252: e168.
    CrossRef

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl